New Alzheimer's drug candidate passes first safety hurdle in small trial
NCT ID NCT05804383
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested the safety of a new drug called BMS-984923 in 51 healthy older adults and people with Alzheimer's disease. Participants received either the drug or a placebo to check for side effects and how the body processes the medication. The goal was to see if the drug is safe enough for further testing, not to measure if it helps symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-984923
What this could lead to
If successful, this could pave the way for a new treatment to control Alzheimer's disease progression.
What could go wrong
This is a very early Phase 1 trial focused only on safety and dosing, not on effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Spaulding Clinical Research
West Bend, Wisconsin, 53095, United States
-
Yale University
New Haven, Connecticut, 06511, United States